Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is hosting a conference call today, February 5, ...
Assistant Controller of Patents (C.A. (COMM.IPD-PAT) 76/2022), the Delhi High Court upheld the refusal of a patent ...
A new scientific review summarizes the growing body of research on wild blueberries and cardiometabolic health, which includes factors like blood vessel function, blood pressure, blood lipids ...
The FDA approved plozasiran (Redemplo) for the reduction of triglycerides in people with familial chylomicronemia syndrome (FCS), the agency announced. The small interfering RNA (siRNA) therapy, ...
What Is Redemplo, and Why Does It Matter? Redemplo (plozasiran) is a type of medicine called a small interfering RNA (siRNA) therapy approved to help lower extremely high triglyceride levels in adults ...
Plozasiran is the first FDA-approved drug for familial chylomicronemia syndrome, reducing triglycerides as an adjunct to diet. The phase 3 PALISADE trial showed significant triglyceride reduction with ...
In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn LDL cholesterol and triglycerides in patients whose levels refused to budge ...
In a small, short-term, Phase 2 clinical trial in adults, a first-of-its-kind medication reduced triglyceride levels in most patients by more than 60%. Called DR10624, the medication activates three ...
Please provide your email address to receive an email when new articles are posted on . Olezarsen reduced triglycerides and the rate of acute pancreatitis events in patients with severely elevated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results